請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10655
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 曹昭懿 | |
dc.contributor.author | Wei-Chun Li | en |
dc.contributor.author | 李瑋君 | zh_TW |
dc.date.accessioned | 2021-05-20T21:47:16Z | - |
dc.date.available | 2016-10-07 | |
dc.date.available | 2021-05-20T21:47:16Z | - |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-18 | |
dc.identifier.citation | 1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929.
2. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194:S3-11. 3. Lau EM, Lee JK, Suriwongpaisal P. The incidence of hip fracture in four Asian countries: The Asian Osteoporosis Study (AOS). Osteoporos Int 2001;12:239-43. 4. Tsai K, Twu S, Chieng P, Yang R, Lee T. Prevalence of vertebral fractures in chinese men and women in urban Taiwanese communities. Calcif Tissue Int 1996;59:249-53. 5. Follin SL, Hansen LB. Current approaches to the prevention and treatment of postmenopausal osteoporosis. Am J Health Syst Pharm 2003;60:883-901; quiz 3-4. 6. Lewiecki EM, Silverman SL. Redefining osteoporosis treatment: Who to treat and how long to treat. Arq Bras Endocrinol Metabol 2006;50:694-704. 7. Riggs BL, Melton LJ. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505S-11S. 8. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 2005;16:S8-S17. 9. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004;22:1153-65. 10. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16 Suppl 2:S3-7. 11. Atkinson SA, Ward WE. Clinical nutrition: 2. The role of nutrition in the prevention and treatment of adult osteoporosis. CMAJ 2001;165:1511-4. 12. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7:390-406. 13. Yang RS, Liu SH. Current pharmacological approaches to prevent and treat postmenopausal osteoporosis. Recent Patients on Endocrine, Metabolic & Immune Drug Discovery 2009;3:42-53. 14. Kelley GA. Aerobic exercise and bone density at the hip in postmenopausal women: a meta-analysis. Prev Med 1998;27:798-807. 15. Lips P, vanSchoor NM. Quality of life in patients with osteoporosis. Osteoporos Int 2005;16:447-55. 16. Orsini LS, Rousculp MD, Long SR, Wang S. Health care utilization and expenditures in the United States: a study of osteoporosis related fractures. . Osteoporos Int 2005;16:359-71. 17. Ostlere SJ, Gold RH. Osteoporosis and bone density measurement methods. Clin Orthop 1991:149-63. 18. Morris R, Masud T. Measuring quality of life in osteoporosis. Age Ageing 2001;30:371-3. 19. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129. 20. Lane NE, Sambrook P. Osteoporosis and the osteoporosis of rheumatic diseases : a companion to Rheumatology. Philadelphia: Mosby/Elsevier; 2006. 21. Buist DSM, LaCroix AZ, Manfredonia D, Abbott T. Identifying postmenopausal women at high risk of fracture in populations: a comparison of three strategies. J Am Geriatr Soc 2002;50:1031-8. 22. Webber CE. Uncertainties in bone mineral density T scores. Clin Invest Med 1998;21:88-93. 23. Bartl R, Frisch B. Subgroups of osteoporosis: from different points of view. In: Osteoporosis : diagnosis, prevention, therapy : a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 33-9. 24. Gass M, Dawson-Hughes B, Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006;119:S3-S11. 25. Riggs BL, Melton LJ. Osteoporosis : etiology, diagnosis, and management. Philadelphia: Lippincott-Raven; 1995. 26. Bartl R, Frisch B. Recognition of risk factors. In: Osteoporosis: diagnosis, prevention, therapy : a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 40-8. 27. Bartl R, Frisch B. Preventive care for lifelong healthy bones. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 80-96. 28. Bartl R, Frisch B. Osteoporosis: a danger lurking in all medical disciplines. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 190-8. 29. Martin AR, Sornay- rendu E, Chandler JM, Duboeuf F, Girman CJ, Delmas PD. The impact of osteoporosis on quality of life: the OFELY cohort. Bone 2002;31:32- 6. 30. Lin JT, Lane JM. Osteoporosis: a review. Clin Orthop 2004;425:126- 34. 31. Levine JP. Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone 2006;8:40-53. 32. Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006;194:S12-23. 33. Ralston SH. Genes and osteoporosis. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment 2nd ed. New York: Springer; 2004: 101-10. 34. Bartl R, Frisch B. Bone: a fascinating organ. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 5-23. 35. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005;20:185-94. 36. Mehta G, Taylor P, Petley G, Dennison E, Cooper C, Walker-Bone K. Bone mineral status in immigrant Indo-Asian women. QJM 2004;97:95-9. 37. Cooper C, Westlake S, Harvey N, Javaid K, Dennison E, Hanson M. Review: developmental origins of osteoporotic fracture. Osteoporos Int 2006;17:337-47. 38. Melton LJ, 3rd, Khosla S, Achenbach SJ, O'Connor MK, O'Fallon WM, Riggs BL. Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men. Osteoporos Int 2000;11:977-83. 39. Bartl R, Frisch B. Osteoporosis: many drugs are bone robbers. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 199-213. 40. McClung MR. Pathophysiology of fractures. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 21-8. 41. Shapses SA, Riedt CS. Bone, body weight, and weight reduction: what are the concerns? J Nutr 2006;136:1453-6. 42. Yang NP, Deng CY, Chou YJ, Chen PQ, Lin CH, Chou P et al. Estimated prevalence of osteoporosis from a Nationwide Health Insurance database in Taiwan. Health Policy 2006;75:329-37. 43. Jordan KM, Cooper C, Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Cl Rh 2002;16:795-806. 44. North American Menopause S. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340-67; quiz 68-9. 45. Layne JE, Nelson ME. The effects of progressive resistance training on bone density: a review. Med Sci Sports Exerc 1999;31:25-30. 46. Stand AP. American College of Sports Medicine Position Stand on Osteoporosis and Exercise. Med Sci Sports Exerc 1995;27:1-7. 47. Prior JC, Barr SI, Chow R, Faulkner RA. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis. CMAJ 1996;155:940-4. 48. Reid IR. Therapy of osteoporosis: Calcium, vitamin D, and exercise. Am J Med Sci. 1996. p 278- 86. 49. Lange U, Teichmann J, Uhlemann C. Current knowledge about physiotherapeutic strategies in osteoporosis prevention and treatment. Rheumatol Int 2005;26:99-106. 50. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Cl Rh 2007;21:109-22. 51. Tudor-Locke C, McColl RS. Factors related to variation in premenopausal bone mineral status: a health promotion approach. Osteoporos Int 2000;11:1-24. 52. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993;8:567-73. 53. Cifuentes M, Johnson MA, Lewis RD, Heymsfield SB, Chowdhury HA, Modlesky CM et al. Bone turnover and body weight relationships differ in normal-weight compared with heavier postmenopausal women. Osteoporos Int 2003;14:116-22. 54. Nguyen TV, Sambrook PN, Eisman JA. Bone loss, physical activity, and weight change in elderly women: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 1998;13:1458-67. 55. Reid IR, Ames RW, Evans MC, Sharpe SJ, Gamble GD. Determinants of the rate of bone loss in normal postmenopausal women. J Clin Endocrinol Metab 1994;79:950-4. 56. Ensrud KE, Fullman RL, Barrett-Connor E, Cauley JA, Stefanick ML, Fink HA et al. Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study. J Clin Endocrinol Metab 2005;90:1998-2004. 57. Langlois JA, Mussolino ME, Visser M, Looker AC, Harris T, Madans J. Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study. Osteoporos Int 2001;12:763-8. 58. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001;21:323-41. 59. Papaioannou A, Kennedy CC, Cranney A, Hawker G, Brown JP, Kaiser SM et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int 2009;20:507-18. 60. Rubin CT, Lanyon LE. Regulation of bone mass by mechanical strain magnitude. Calcif Tissue Int 1985;37:411-7. 61. Prouteau S, Benhamou L, Courteix D. Relationships between serum leptin and bone markers during stable weight, weight reduction and weight regain in male and female judoists. Eur J Endocrinol 2006;154:389-95. 62. Takeda S. Central control of bone remodeling. Biochem Biophys Res Commun 2005;328:697-9. 63. Jen KLC, Buison A, Darga L, Nelson D. The relationship between blood leptin level and bone density is specific to ethnicity and menopausal status. J Lab Clin Med 2005;146:18-24. 64. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005;331:520-6. 65. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone 2005;37:359-69. 66. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsb, x00F, ll T et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003;18:2180-9. 67. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-3. 68. Holick MF, Holick MF. The vitamin D epidemic and its health consequences. J Nutr 2005;135:2739S-48S. 69. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003;89:552-72. 70. Liu XD, Zhu YK, Umino T, Spurzem JR, Romberger DJ, Wang H et al. Cigarette smoke inhibits osteogenic differentiation and proliferation of human osteoprogenitor cells in monolayer and three-dimensional collagen gel culture. J Lab Clin Med 2001;137:208-19. 71. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990;162:502-14. 72. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 1997;155:1770-6. 73. Turner RT. Skeletal response to alcohol. Alcohol Clin Exp Res 2000;24:1693-701. 74. Feskanich D, Korrick SA, Greenspan SL, Rosen HN, Colditz GA. Moderate alcohol consumption and bone density among postmenopausal women. J Womens Health 1999;8:65-73. 75. Chavassieux P, Serre CM, Vergnaud P, Delmas PD, Meunier PJ. In vitro evaluation of dose-effects of ethanol on human osteoblastic cells. Bone Miner 1993;22:95-103. 76. Cheung RC, Gray C, Boyde A, Jones SJ. Effects of ethanol on bone cells in vitro resulting in increased resorption. Bone 1995;16:143-7. 77. Turner RT, Wronski TJ, Zhang M, Kidder LS, Bloomfield SA, Sibonga JD. Effects of ethanol on gene expression in rat bone: transient dose-dependent changes in mRNA levels for matrix proteins, skeletal growth factors, and cytokines are followed by reductions in bone formation. Alcohol Clin Exp Res 1998;22:1591-9. 78. Burckhardt P. Nutrition and osteoporosis. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 187-92. 79. Kitchin B, Morgan S, Kitchin B, Morgan S. Nutritional considerations in osteoporosis. Curr Opin Rheumatol 2003;15:476-80. 80. Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr 2005;81:1232S-9S. 81. Nordin BE. Calcium and osteoporosis. Nutrition 1997;13:664-86. 82. Heaney RP. Calcium, dairy products and osteoporosis. J Am Coll Nutr 2000;19:83S-99S. 83. Welten DC, Kemper HC, Post GB, van Staveren WA. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. J Nutr 1995;125:2802-13. 84. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552-9. 85. Montero-Odasso M, Duque G, Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med 2005;26:203-19. 86. Pfeifer M, Begerow B, Minne HW, Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporos Int 2002;13:187-94. 87. Venning G. Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ 2005;330:524-6. 88. Janssen HC, Samson MM, Verhaar HJ, Janssen HCJP, Samson MM, Verhaar HJJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002;75:611-5. 89. National Institutes of Health (NIH) Osteoporosis and Related Bone Diseases- National Resource Center. Nutrition and bone health [cited 2010. 02.03]. Available from: URL: http://www.niams.nih.gov/Health_info/Bone/Bone_Health/Nutrition/default.asp. 90. Kenny AM, Biskup B, Robbins B, Marcella G, Burleson JA. Effects of vitamin D supplementation on strength, physical function, and health perception in older, community-dwelling men. J Am Geriatr Soc 2003;51:1762-7. 91. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6. 92. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42. 93. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009;339:b3692. 94. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15:1113-8. 95. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY et al. Effect of Vitamin D on Falls: A Meta-analysis. JAMA 2004;291:1999-2006. 96. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469. 97. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560-9. 98. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 2000;72:745-50. 99. Ginty F, Ginty F. Dietary protein and bone health. Proc Nutr Soc 2003;62:867-76. 100. Kim J, Lim SY, Kim JH, Kim J, Lim S-Y, Kim J-H. Nutrient intake risk factors of osteoporosis in postmenopausal women. Asia Pac J Clin Nutr 2008;17:270-5. 101. Burns L, Ashwell M, Berry J, Bolton-Smith C, Cassidy A, Dunnigan M et al. UK Food Standards Agency Optimal Nutrition Status Workshop: environmental factors that affect bone health throughout life. Br J Nutr 2003;89:835-40. 102. Atmaca A, Kleerekoper M, Bayraktar M, Kucuk O, Atmaca A, Kleerekoper M et al. Soy isoflavones in the management of postmenopausal osteoporosis. Menopause 2008;15:748-57. 103. Wong WW, Lewis RD, Steinberg FM, Murray MJ, Cramer MA, Amato P et al. Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial. Am J Clin Nutr 2009;90:1433-9. 104. Tucker KL. Dietary Intake and Bone Status with Aging. Curr Pharm Des 2003;9:2687-704. 105. Bartl R, Frisch B. Calcium and vitamin D: the skeleton's best friends. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 109-16. 106. McCann JC, Ames BN, McCann JC, Ames BN. Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? Am J Clin Nutr 2009;90:889-907. 107. Ribaya-Mercado JD, Blumberg JB. Vitamin A: is it a risk factor for osteoporosis and bone fracture? Nutr Rev 2007;65:425-38. 108. Melhus H, Michaelsson K, Kindmark A, Bergstrom R, Holmberg L, Mallmin H et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med 1998;129:770-8. 109. Cooper C, Woolf AD. Osteoporosis : best practice & research compendium. New York: Elsevier; 2006. 110. NIH (National Institutes of Health) Fact Sheet. Vitamin B12 sources [cited 2008. 02.25.]. Available from: URL: http://ods.od.nih.gov/factsheets/vitaminb12.asp#h2. 111. Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo Study. JAMA 1994;271:280-3. 112. Harris SS, Dawson-Hughes B. Caffeine and bone loss in healthy postmenopausal women. Am J Clin Nutr 1994;60:573-8. 113. Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001;74:694-700. 114. Rapuri PB, Gallagher JC, Balhorn KE, Ryschon KL. Alcohol intake and bone metabolism in elderly women. Am J Clin Nutr 2000;72:1206-13. 115. Ganry O, Baudoin C, Fardellone P. Effect of alcohol intake on bone mineral density in elderly women: The EPIDOS Study. Am J Epidemiol 2000;151:773-80. 116. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-9. 117. Pinheiro MM, Schuch NJ, Genaro PS, Ciconelli RM, Ferraz MB, Martini LA et al. Nutrient intakes related to osteoporotic fractures in men and women-the Brazilian Osteoporosis Study (BRAZOS). Nutrition Journal 2009;8:6-13. 118. Chachra D, Vieira AP, Grynpas MD, Chachra D, Vieira APGF, Grynpas MD. Fluoride and mineralized tissues. Crit Rev Biomed Eng 2008;36:183-223. 119. Bartl R, Frisch B. Hormones for replacement: a matter of re- evaluation. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 117- 27. 120. Bartl R, Frisch B. Osteoporosis: men are also victims, but with a time lag. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 174-9. 121. Vanderschueren D, Boonen S, Bouillon R. Physiology of calcium homeostasis and bone remodeling. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 9-14. 122. Geusens P, Lindsay R. Anabolic drug therapy in osteoporosis. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 143-6. 123. Bartl R, Frisch B. Parathormone: a promising osteoanabolic agent. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 148-50. 124. Bartl R, Frisch B. Additional medications. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 151-4. 125. Bassett JHD, Nordstrom K, Boyde A, Howell PGT, Kelly S, Vennstrom B et al. Thyroid status during skeletal development determines adult bone structure and mineralization. Mol Endocrinol 2007;21:1893-904. 126. Bassett JHD, Williams GR. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab 2003;14:356-64. 127. Bassett JHD, Williams AJ, Murphy E, Boyde A, Howell PGT, Swinhoe R et al. A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol 2008;22:501-12. 128. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 2010;21:294-301. 129. Canalis E, Delany AM, Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002;966:73-81. 130. de Villiers TJ, de Villiers TJ. Bone health and osteoporosis in postmenopausal women. Best Pract Res Cl Ob 2009;23:73-85. 131. Vondracek SF. Managing osteoporosis in postmenopausal women. Am J Health Syst Pharm 2010;67:S9-19. 132. Durosier C, Hans D, Krieg MA, Schott AM, Durosier C, Hans D et al. Prediction and discrimination of osteoporotic hip fracture in postmenopausal women. J Clin Densitom 2006;9:475-95. 133. Benetos IS, Babis GC, Zoubos AB, Benetou V, Soucacos PN, Benetos IS et al. Factors affecting the risk of hip fractures. Injury 2007;38:735-44. 134. El-Kaissi S, Pasco JA, Henry MJ, Panahi S, Nicholson JG, Nicholson GC et al. Femoral neck geometry and hip fracture risk: the Geelong osteoporosis study. Osteoporos Int 2005;16:1299-303. 135. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82. 136. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;12:S1- S27. 137. Cummings SR, Cauley JA, Palermo L, Ross PD, Wasnich RD, Black D et al. Racial differences in hip axis lengths might explain racial differences in rates of hip fracture. Study of Osteoporotic Fractures Research Group. Osteoporos Int 1994;4:226-9. 138. Mikhail MB, Vaswani AN, Aloia JF, Mikhail MB, Vaswani AN, Aloia JF. Racial differences in femoral dimensions and their relation to hip fracture. Osteoporos Int 1996;6:22-4. 139. Dibba B, Prentice A, Laskey MA, Stirling DM, Cole TJ. An investigation of ethnic differences in bone mineral, hip axis length, calcium metabolism and bone turnover between West African and Caucasian adults living in the United Kingdom. Ann Hum Biol 1999;26:229-42. 140. Faulkner KG, McClung M, Cummings SR, Faulkner KG, McClung M, Cummings SR. Automated evaluation of hip axis length for predicting hip fracture. J Bone Miner Res 1994;9:1065-70. 141. Buencamino MC, Sikon AL, Jain A, Thacker HL, Buencamino MCA, Sikon AL et al. An observational study on the adherence to treatment guidelines of osteopenia. J Womens Health 2009;18:873-81. 142. Yan L, Crabtree NJ, Reeve J, Zhou B, Dequeker J, Nijs J et al. Does hip strength analysis explain the lower incidence of hip fracture in the People's Republic of China? Bone 2004;34:584-8. 143. Chin K, Evans MC, Cornish J, Cundy T, Reid IR. Differences in hip axis and femoral neck length in premenopausal women of Polynesian, Asian and European origin. Osteoporos Int 1997;7:344-7. 144. Theobald TM, Cauley JA, Gluer CC, Bunker CH, Ukoli FA, Genant HK. Black-white differences in hip geometry. Study of Osteoporotic Fractures Research Group. Osteoporos Int 1998;8:61-7. 145. Anonymous. What to do about postmenopausal fracture risk. Diet, exercise, calcium, and vitamin D are always important, but women at high risk for fractures may need drug therapy, too. Harvard Women's Health Watch 2009;17:1-3. 146. Bartl R, Frisch B. Osteoporotic fractures can be treated successfully but should now be avoided. In: Osteoporosis : diagnosis, prevention, therapy : a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 155-73. 147. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP et al. A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int 2001;12:699-705. 148. Tao B, Liu JM, Li XY, Wang JG, Wang WQ, Ning G et al. An assessment of the use of quantitative ultrasound and the Osteoporosis Self-Assessment Tool for Asians in determining the risk of nonvertebral fracture in postmenopausal Chinese women. J Bone Miner Metab 2008;26:60-5. 149. Geusens P, Ross PD. Future developments: risk assessment. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 109-208. 150. Sen SS, Rives VP, Messina OD, Morales-Torres J, Riera G, Angulo-Solimano JM et al. A risk assessment tool (OsteoRisk) for identifying Latin American women with osteoporosis. J Gen Intern Med 2005;20:245-50. 151. Licata AA. Update on therapy for osteoporosis. Orthop Nurs 2007;26:162-6; quiz 7-8. 152. NOF. Osteoporosis medications [cited 2010. 02.21.]. Available from: URL: http://www.nof.org/patientinfo/medications.htm. 153. Cefalu CA, Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004;20:341-9. 154. Stevenson JC. Prevention early after menopause. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 111-8. 155. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428. 156. Bartl R, Frisch B. Osteoporosis: even more harmful in children. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004:180-9. 157. Chesnut CH, 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76. 158. Boonen S, Haentjens P, Vanderschueren D. Pharmacologic and non- pharmacologic strategies to prevent hip fracture in old age. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 119-28. 159. Bartl R, Frisch B. Raloxifene: a potent selective oestrogen receptor modulator (SERM). In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 145-7. 160. Lindsay R. Selective estrogen receptor modulators. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice : a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 129-32. 161. National Osteoporosis Society. Osteoporosis medications [cited 2010. 11.23.]. Available from: URL: http://www.nos.org.uk/NetCommunity/Page.aspx?pid=264. 162. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41. 163. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. 164. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17. 165. Jolly EE, Bjarnason NH, Neven P, Plouffe L, Jr., Johnston CC, Jr., Watts SD et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44. 166. Neele SJM, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603. 167. Bone H. Bisphosphonate therapy for postmenopausal osteoporosis. In: Geusens P, Sambrook P, Lindsay R, editors. Osteoporosis in clinical practice: a practical guide for diagnosis and treatment. 2nd ed. New York: Springer; 2004: 133-42. 168. Bartl R, Frisch B. Bisphosphonates: the success story in osteoporosis. In: Osteoporosis: diagnosis, prevention, therapy: a practical guide for all physicians--from pediatrics to geriatrics. New York: Springer; 2004: 128-44. 169. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. 170. Tournis S, Economopoulos D, Lyritis GP. Strontium Ranelate: A Novel Treatment in Postmenopausal Osteoporosis. Ann N Y Acad Sci 2006;1092:403-7. 171. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68. 172. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006;22:1249-56. 173. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22. 174. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes FaNBIoM. Calcium and related nutrients: overview and methods. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington (DC): National Academy Press; 2003. p 38- 53. 175. Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures: the Framingham Study. Am J Epidemiol 1988;128:1102-10. 176. Lord SR, Menz HB, Sherrington C. Falls in older people. In: Geusens P, Sam | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10655 | - |
dc.description.abstract | 隨著老年人口的快速增加,骨質疏鬆已成為一個全球性的公共衛生課題,亞洲地區及台灣也不例外。骨質疏鬆病患骨密度會降低且骨組織構造會受到破壞,導致骨頭變得較脆弱,容易引發骨折,而骨折後所引發的相關併發症與後遺症往往帶給醫療及社會相當大的成本與負擔。運動治療無副作用,對於這類病患是極被推薦的非藥物性治療方式,運動對於增加骨密度、減緩骨流失、預防跌倒等成效已被很多研究證實,但對於不同運動介入方式所產生之效益的研究則頗為有限。對於醫療提供者而言,如何能達到有效益又可節省成本是重要的考量。因此,本研究之目的為:研究一,探討不同運動介入方式,包含居家運動組、群體運動組及衛教組之療效差異;研究二,比較三種執行方案之成本效益。
研究一設計為前瞻性隨機分組臨床試驗,共徵召87名50歲以上停經後骨質疏鬆婦女以隨機分組介入的方式,探討居家運動組、群體運動組及衛教組之療效差異,運動介入時間為三個月,在介入前、介入停止後及追蹤至一年各有一次評估,評估項目包括:骨密度(於6個月時做第二次評估)、肌力、平衡能力、功能活動、生活品質、與跌倒次數。資料分析以SPSS 11.0版本作為統計分析之工具,所有分析之α值定在0.05。將以敘述性統計呈現三組基本資料的特性;以Kruskal- Wallis test檢測三組在各個不同時間點組間之差異。以Friedman test檢測各組在不同時間點之組內差異。研究二進行上述三方案之成本效益分析:成本為執行方案所需之經費,效益為骨密度、肌力、平衡能力、功能活動、生活品質及跌倒次數之改變;以及與衛教組比較所增加之成本效益比。 研究一結果顯示,各組在運動介入後大部分變數均有進步之趨勢。在各個不同時間點,三組間在各變項均無顯著差異(p> 0.05)。故將三組結果加以整合分析,結果顯示上肢抓握力相較於第一及第二次測試,在第三次之測試有顯著進步;功能活動、平衡及整體生活品質表現,第一次與第二次及第三次之測試間有顯著進步。而跌倒的人次,在介入完成後半年內三種執行方式均有明顯減少。 研究二結果顯示,對於提高病患生活品質而言,居家運動為三種模式中最符合成本效益之方式。而對於跌倒的預防,衛教組最具成本效益。當以不同方式支付治療費用及不考慮產值損失時,敏感度分析結果並未改變。然而不考慮產值損失時,居家運動組幾乎為大部分變項中最具成本效益的介入模式。 由介入結果可提出結論,三種不同運動執行方式對功能活動及減少跌倒的效益是相近的,未來對於此類病患教導其執行居家運動並給予完整的疾病相關衛教應是避免骨質疏鬆及預防跌倒的有效方式。若加入成本之考量,衛教及居家運動皆為較符合成本效益的執行方式。 | zh_TW |
dc.description.abstract | Elderly population is rapidly increasing in number and proportion, osteoporosis has become a major global public health issue, including Asia and Taiwan. Osteoporosis is a systemic disorder and is characterized by low bone mass, leading to bone fragility and an increased susceptibility to fractures. The complications and sequelae that coming with osteoporotic fractures always cause great burden to the society and medical care system. Many studies have proven that exercise can improve the bone mineral density, decrease bone loss, prevent fall and so on. However, most studies focused on the effects of different types of exercises, few studies compared the therapeutic effects among different delivery modes. To the medical providers, what is the most cost-effective program is important. The purposes of this thesis are as follows: Study 1: To compare the effectiveness of home-based exercise, group exercise and education group. Study 2: To conduct a cost-effectiveness analysis (CEA) for the 3 programs and the incremental cost effectiveness analysis (ICEA) comparing with the education group. Study I was a prospective randomized controlled trial. Eighty seven postmenopausal women with osteoporosis and age older than 50 years old were recruited. They were randomized into home-based exercise, group exercise or education group. The intervention was for 3 months, evaluation was done before and after the intervention and one year after starting the program. The outcome measures included: bone mineral density (BMD: the second evaluation was done at the 6th month), muscle strength, balance, functional mobility, quality of life, and numbers of fall. Data was analysed using the 11.0 version of SPSS and a was set at 0.05 for all analyses. Descriptive statistics was used to show the baseline characteristics of the three groups. Kruskal–Wallis test was used to compare difference among groups. Friedman test was used to analyze the differences among all three time points within the groups. Study II, a CEA and ICEA for the 3 programs was executed. The cost was based on the budget for performing the programs, and the effectiveness was measured including the changes in BMD, muscle strength, balance, functional mobility, quality of life, and numbers of fall. The result of study I showed that three groups had a trend of improvement in most outcomes. There was almost no significant difference among three groups at each time point (p> 0.05). The data of all modes was pooled together, the results showed that grip strength had significant improvement at 12- month follow- up comparing to baseline and 3- month assessments; functional mobility, balance (using one leg standing with eyes opened), and total score of Qualeffo- 31 all showed significant improvements between baseline and 3- month and between baseline and 12- month assessment (p< 0.05). All fall numbers of 3 modes declined till half year after intervention. The results of study II showed that home- based exercise was the most cost effective one among 3 delivery modes of exercise for improving QOL. For fall prevention, education program might be the most cost effectiveness program. The sensitivity analysis was conducted, the results did not change. However, if the productivity cost was neglected, home- based exercise was the most cost- effective option in most variables. We concluded that all 3 modes of exercise could get similar effects on mobility and lowering the fall risk. A comprehensive education program with home exercise program may be an effective way to prevent osteoporosis and fall. When cost effectiveness is considered, education program or home- based exercise may be the better options. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T21:47:16Z (GMT). No. of bitstreams: 1 ntu-100-D94428005-1.pdf: 1852109 bytes, checksum: 1992448cbe21919b6ed5c610c7c9876c (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員審定書 i
誌謝 ii 中文摘要 iii Abstract v List of figures xi List of tables xii Chapter 1 Introduction 1 1.1 Background 1 1.2 Purposes of this study 1 1.2.1 Purpose of study 1 2 1.2.2 Purpose of study 2 2 Chapter 2 Literature review 4 2.1 Global problem of osteoporosis 4 2.2 Classification of osteoporosis 5 2.3 Risk factors of osteoporosis 8 2.3.1 Risk factors which cannot be modified: genetics, race, gender, age, and family history 9 2.3.2 Risk factors which can be modified: physical activity, body weight, smoke, alcohol, nutrition, hormones, medications and diseases 11 2.4 Risk factors of osteoporotic fractures 46 2.4.1 Risk factors which cannot be modified: advanced age, gender, low BMD, previous fracture history and family osteoporotic fracture history, race 47 2.4.2 Risk factors which can be modified: life style, medical disease, low body weight, medications, risk factors for falling 50 2.5 Self screening tool for risk of osteoporosis and osteoporotic fracture: OSTA (the osteoporosis self assessment tool for Asians) 52 2.6 Treatment of osteoporosis 54 2.6.1 Pharmacological therapy 54 2.6.2 Nonpharmacologic therapy 67 2.7 Management for reducing fracture risk 70 2.7.1 Exercise 70 2.7.2 Change lifestyle 70 2.7.3 Fall prevention 71 2.8 Physical activity for osteoporosis and osteoporotic fractures 74 2.8.1 Effects of exercise on BMD 76 2.8.2 Effects of exercise on fall 83 2.8.3 Effects of exercise on preventing osteoporotic fractures 87 2.8.4 Exercise prescription 90 2.9 Quality of life of osteoporosis 93 2.9.1 Quality of life of osteoporotic population 93 2.9.2 Exercise effects on quality of life 94 2.9.3 Measurement of quality of life 96 2.10 Economic evaluation 102 2.10.1 Cost effectiveness analysis 102 2.10.2 Economic evaluation of osteoporosis 104 Chapter 3 Materials and Methods 107 3.1 Study 1: Comparison of the effects of different delivery modes of exercises for postmenopausal women with osteoporosis 107 3.1.1 Study design 107 3.1.2 Procedure 107 3.1.3 Participants 108 3.1.4 Outcome measures 110 3.1.5 Training programs 115 3.1.6 Statistical analysis 124 3.2 Study 2: Cost effectiveness analysis of different delivery modes of exercises for postmenopausal women with osteoporosis 125 3.2.1 Study design 125 3.2.2 Participants 125 3.2.3 Procedure 125 3.2.4 Measurement 126 Chapter 4 Results and discussions 133 4.1 Study 1 133 4.1.1 Results of study 1 133 4.1.2 Discussions of study 1 134 4.1.3 Conclusions of study 1 138 4.2 Study 2 140 4.2.1 Results of study 2 140 4.2.2 Discussions of study 2 143 4.2.3 Conclusions of study 2 147 Figures 149 Tables 151 References 173 | |
dc.language.iso | en | |
dc.title | 停經後骨質疏鬆婦女運動訓練計畫之效果與成本評估 | zh_TW |
dc.title | Effectiveness and Cost Analysis of Exercise Programs for Postmenopausal Women with Osteoporosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 楊榮森,蔡克嵩,王儷穎,黃貴薰 | |
dc.subject.keyword | 骨質疏鬆,停經後婦女,衛教,居家運動,群體運動,成本效益分析, | zh_TW |
dc.subject.keyword | osteoporosis,postmenopausal women,education program,home based exercise,group exercise,cost- effectiveness analysis, | en |
dc.relation.page | 211 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2011-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 物理治療學研究所 | zh_TW |
顯示於系所單位: | 物理治療學系所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf | 1.81 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。